ArticleThe Journal of antibiotics2026
Isolation of N-acetylallosaminylallosamidin, a new pseudotetrasaccharide allosamidin congener.
Article in The Journal of antibiotics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Allosamidin is a metabolite produced by Streptomyces species, known for its inhibitory activity against family 18 chitinases. All known natural congeners of allosamidin are pseudotrisaccharides featuring a cyclopentane moiety fused with an aminooxazoline ring. We discovered a novel allosamidin congener produced by Streptomyces sp. No. 1-5-6, an allosamidin producer newly isolated from soil. Although its yield was very low, its structure was elucidated by NMR and MS analyses as N-acetylallosaminylallosamidin, the first natural allosamidin congener with a pseudotetrasaccharide structure. N-Acetylallosaminylallosamidin inhibited bacterially expressed mouse acidic mammalian chitinase with an IC₅₀ value of 102.3 nM, showing strong activity, albeit slightly weaker than that of allosamidin.
Indexed as
Identifiers
41735569What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.